20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.30% | 17.25% | 32.35% | 30.91% | 31.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.30% | 17.25% | 32.35% | 30.91% | 31.13% |
| Cost of Revenue | -6.11% | 4.06% | 7.15% | 15.19% | 16.18% |
| Gross Profit | 14.43% | 68.14% | 175.89% | 114.33% | 126.66% |
| SG&A Expenses | -13.03% | -29.91% | -29.82% | -0.96% | 0.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.44% | -27.85% | -22.72% | -1.45% | -2.40% |
| Operating Income | 23.30% | 41.81% | 37.46% | 10.78% | 10.70% |
| Income Before Tax | -0.18% | 33.34% | 35.45% | 8.20% | 9.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.18% | 33.34% | 35.45% | 8.20% | 9.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.18% | 33.34% | 35.45% | 8.20% | 9.08% |
| EBIT | 23.30% | 41.81% | 37.46% | 10.78% | 10.70% |
| EBITDA | 22.99% | 41.93% | 37.64% | 10.50% | 10.61% |
| EPS Basic | 31.86% | 26.74% | 27.58% | -0.26% | 1.32% |
| Normalized Basic EPS | 11.40% | 49.02% | 49.88% | 24.27% | 23.63% |
| EPS Diluted | 31.89% | 26.79% | 27.72% | -0.48% | 1.12% |
| Normalized Diluted EPS | 11.40% | 49.02% | 49.88% | 24.27% | 23.63% |
| Average Basic Shares Outstanding | 75.68% | -22.41% | -24.03% | -24.24% | -24.43% |
| Average Diluted Shares Outstanding | 31.66% | 2.70% | 1.16% | 1.01% | 0.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |